Inmune Bio (INMB) Receivables - Other (2019 - 2026)
Inmune Bio's Receivables - Other came in at $354,000 for Q2 2026, down 35.6% from $550,000 a year earlier but up 21.6% from the prior quarter.
Analysis
Inmune Bio (INMB) Receivables - Other (2019 - 2026) Analysis & Trends
At the end of FY2025, Inmune Bio's Receivables - Other was $257,000, up 12.7% from FY2024.
- Receivables - Other carries a four-year compound annual growth rate of -3.8% (FY2021 to FY2025).
- Going back by year, Receivables - Other was $228,000 in FY2024 (-57.5%), $537,000 in FY2023 (+48.3%), $362,000 in FY2022 (+20.7%) and $300,000 in FY2021.
- The five-year range for quarterly Receivables - Other is $100,000 (Q3 2022) to $760,000 (Q3 2025).
- Year-over-year, Receivables - Other increased in three of the last seven quarters, with an average decline of 0.7%.
- The fastest year-over-year change in Receivables - Other over five years came in Q1 2026 (growth of 118.8%), and the weakest in Q1 2025 (a decline of 76.1%).
- Business Quant data shows INMB's Receivables - Other at $291,000 (Q1 2026), $257,000 (Q4 2025) and $760,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Inmune Bio | 30.71 Mn | -50.14 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 519,000.00 |
| Jun 30, 2026 | 354,000.00 |
| Mar 31, 2026 | 291,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 760,000.00 |
| Jun 30, 2025 | 550,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Dec 31, 2024 | 228,000.00 |
| Sep 30, 2024 | 545,000.00 |
| Jun 30, 2024 | 590,000.00 |
| Mar 31, 2024 | 557,000.00 |
| Dec 31, 2023 | 537,000.00 |
| Dec 31, 2022 | 362,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 200,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Dec 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 150,000.00 |
| Sep 30, 2020 | 150.00 Bn |
| Dec 31, 2019 | 850,000.00 |
API Access
Inmune Bio Receivables - Other API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-other&ticker=INMB&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-other", "ticker": "INMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=receivables-other&ticker=INMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();